|
Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced that the United States Patent and Trademark Office issued US Patent No. 12,090,139 to the company on September, 17, 2024. The patent, entitled “Formulations Comprising Triptan Compounds”, claims a pharmaceutical composition, a method of treating migraine via intranasal administration, and an intranasal delivery system for Tosymra. This patent, excluding possible patent term extensions, is expected to expire in 2030.
“We believe this patent further solidifies Tosymra in the market as a differentiated drug with a differentiated administration method,” said Seth Lederman, M.D., chief executive officer of Tonix Pharmaceuticals. “This new patent targets specific delivery and composition. We are thrilled to have these additional issued patent claims, which add to the intellectual property protection existing for Tosymra.”
Nearly 40 million people in the United States suffer from migraine and it has been recognized as the second leading cause of disability in the world. Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity often associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia).
Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges.
|